Cardinal Health, Inc. (NYSE:CAH) Citi's 2024 Global Healthcare Conference Call December 3, 2024 8:00 AM ET Company Participants Aaron Alt - Chief Financial Officer Matt Sims - Head, Investor Relations Conference Call Participants Daniel Grosslight - Citi Daniel Grosslight Thanks for joining us for the Cardinal Health fireside chat here at Citi's Global Healthcare Conference. My name is Daniel Grosslight. For those of you who don't know me, I'm the health tech and distribution analyst here at Citi. I'm very ...

Cardinal Health (CAH) recently launched the Kendall SCD SmartFlow Compression System in the United States. The system is the next generation of the Kendall Compression Series, offering an enhanced clinician and patient experience.Kendall SCD SmartFlow Compression System is designed to help prevent venous thromboembolism events, enhance blood circulation and treat pain and swelling related to venous stasis.Likely Trend of CAH Stock Following the NewsFollowing the announcement, shares of the company moved mov ...

Cardinal Health, Inc. (NYSE:CAH) UBS Global Healthcare Conference November 12, 2024 11:00 AM ET Company Participants Matt Sims - Vice President, Investor Relations Aaron Alt - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Kevin Caliendo Good morning, everybody. Welcome to the UBS Healthcare Global Healthcare Conference. I'm Kevin Caliendo, health care, IT and distribution analyst. And with us this morning is the management of Cardinal Health. Aaron Alt, CFO; and Matt Sims, Direct ...

Summary of Cardinal Health, Inc. Conference Call Company Overview - **Company**: Cardinal Health, Inc. (NYSE: CAH) - **Event**: UBS Global Healthcare Conference - **Date**: November 12, 2024 Key Announcements 1. **Acquisition of GI Alliance**: - Cardinal Health will acquire a majority stake in GI Alliance, the largest gastroenterology MSO platform in the U.S. - This acquisition is seen as a strategic move to expand into other therapeutic areas beyond GI, supporting Cardinal's broader specialty strategy [4][10][36]. 2. **Acquisition of ADSG**: - Cardinal Health announced the acquisition of ADSG, a large distributor of Continuous Glucose Monitoring (CGM) devices, which complements its existing at-home business. - The acquisition is characterized as low CapEx and synergistic, enhancing Cardinal's capabilities in diabetes management [5][18]. 3. **Investor Day Announcement**: - An Investor Day is scheduled for June 12, 2025, to discuss the strategic direction and performance of the company [7]. 4. **Acquisition of Integrated Oncology Network (ION)**: - This acquisition, announced in September, represents Cardinal's entry into the specialty therapeutic area of oncology, further diversifying its portfolio [7]. Strategic Insights - **Ecosystem Development**: - The acquisitions are part of Cardinal's strategy to create a broader ecosystem within the medical field, integrating various specialties and enhancing service offerings [9][10][36]. - **Focus on Specialty Areas**: - Cardinal Health is shifting focus towards higher-margin, higher-growth areas, particularly in specialty pharmaceuticals and oncology, to address strategic gaps in its portfolio [33][34]. - **Operational Efficiency**: - Cardinal has restructured its reporting segments to elevate the visibility and investment in its at-home business and other previously hidden segments, indicating a commitment to growth in these areas [16][17]. Financial Performance and Market Dynamics - **CGM Market Growth**: - The CGM market is projected to grow at a 10% CAGR, driven by legislative changes and increased access to CGMs for diabetes patients [19][20]. - **GLP-1 Therapy**: - GLP-1 therapies are a growing part of Cardinal's pharmaceutical distribution business, complementing CGM devices rather than competing with them [21][22]. - **Impact of Tariffs**: - Cardinal is better prepared for potential tariffs due to improved supply chain resilience and contract flexibility, allowing for proactive adjustments in sourcing and pricing [45][47]. Challenges and Considerations - **Onboarding New Customers**: - The transition from Optum to new managed care customers may involve onboarding costs, but these have been accounted for in the company's guidance [70][72]. - **Market Volatility**: - Cardinal acknowledges the uncertainty in the market, particularly regarding the impact of tariffs and the evolving landscape of pharmaceutical distribution [48][49]. Conclusion - Cardinal Health is actively pursuing strategic acquisitions to enhance its service offerings and market position in specialty pharmaceuticals. The company is focused on operational efficiency and adapting to market changes while preparing for future growth opportunities in the healthcare sector.

Cardinal Health (CAH) recently announced that it has entered into definitive agreements to acquire two companies. These agreements are likely to accelerate Cardinal Health's strategic growth areas along with enhancing patient care. CAH is likely to acquire a majority stake in GI Alliance ("GIA"), along with acquiring the Advanced Diabetes Supply Group ("ADSG"). GIA is the country's leading gastroenterology management services organization ("MSO"), from a combination of GIA physician owners and funds managed ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Cardinal Health (CAH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Cardinal Health is one of 1024 companies in the Medical group. The Medical group currently sits at #3 ...

Group 1 - GI Alliance (GIA) has entered into a definitive agreement with Cardinal Health to acquire a majority stake in GIA, valuing the company at $3.9 billion [1] - The partnership aims to create a physician-led, national specialty healthcare platform focused on high-quality specialty care for patients [2] - GIA partners with over 900 physicians across more than 345 locations in 20 states, providing a complete continuum of gastroenterology care [2][5] Group 2 - Cardinal Health's CEO emphasized the importance of reinforcing and expanding their Specialty business through this acquisition, combining GIA's expertise in gastroenterology with Cardinal Health's national scale [3] - The transaction is subject to customary closing conditions, including regulatory approvals [4] - GI Alliance is recognized as the leading physician-led network for gastrointestinal care in the U.S., supporting independent gastroenterologists [5]

Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategy Company announces plan to hold Investor Day in June 2025 DUBLIN, Ohio, Nov. 11, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) annou ...

Michael (Mike) Dion is an FP&A, Corporate Finance, and Small Business expert who spent the last 12 years working in the Fortune 100, building a startup's finance and accounting department, advising small businesses, and guiding non-profit organizations as a board member. He has finance experience across multiple industries, including Telecom, Media and Entertainment, Hospitality, and Construction. He founded F9 Finance, a website that helps Finance professionals accelerate their careers; and simplifies Fina ...

Core Insights - Cardinal Health reported better-than-expected first-quarter profit and sales, driven by growing demand from existing customers [1] - Despite a revenue decline in its largest division, Pharmaceutical & Specialty Solutions, the company indicated that revenue would have increased by 16% year-over-year without the loss of a significant contract [1] - The company raised its full-year EPS guidance, and its shares reached a new all-time intraday high [1] Financial Performance - The company reported fiscal 2025 first-quarter adjusted earnings per share (EPS) of $1.88, exceeding analyst forecasts [1] - Revenue decreased by 4% year-over-year to $52.28 billion, but still surpassed consensus estimates [1] - Sales in the Pharmaceutical and Specialty Solutions unit fell by 5% to $48.0 billion due to the expiration of a distribution contract with OptumRx; however, excluding this impact, revenue would have increased by 16% [1] Segment Performance - Revenue in the Global Medical Products and Distribution segment rose by 3% to $3.1 billion, attributed to higher volumes from existing customers [1] - Other revenue surged by 13% to $1.2 billion, driven by "at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics" [1] Future Outlook - Cardinal Health now projects full-year EPS in the range of $7.75 to $7.90, an increase from the previous guidance of $7.55 to $7.70 [1] - Following the earnings report, shares of Cardinal Health increased nearly 7% to $115.76, with an earlier peak of $119.12 [1]